诺和灵30R和诺和锐30治疗2型糖尿病的疗效比较

目的:探讨和比较诺和灵30R和诺和锐30在2型糖尿病患者中的临床疗效。方法:选取2011年1～12月我院收治的92例2型糖尿病患者,随机分成诺和锐30组和诺和灵30R组,每组46例。两组分别给予诺和锐30和诺和灵30R治疗,比较两组的临床疗效。结果:与诺和灵30R组相比,诺和锐30组治疗后的餐后2h血糖明显降低,两组比较有统计学差异(P<0.05);同时,诺和锐30组低血糖发生率明显降低,住院时间明显缩短,胰岛素应用剂量明显减少,差异均具有统计学意义(P均<0.05)。结论:诺和锐30在提高患者的治疗效果和依从性的同时,减轻了患者的经济负担,适于临床推广应用。

Efficacy comparison of Novolin 30R and Aspart 30 on type 2 diabetes

Objective: To explore and compare the efficacy of Novolin 30R and Aspart 30 on type 2 diabetes.Methods: A total of 92 type 2 diabetes patients that were treated in our hospital during January 2011 to December 2011 were selected and divided into Aspart 30 group and Novolin 30R group randomly with 46 cases in each group.Patients in the two groups were treated with Aspart 30 and Novolin 30R respectively,clinical efficiency were compared between the two groups.Results: Compared with Novolin 30R group,the 2h postprandial blood glucose level of the Aspart 30 group after treatment were significant lower(P<0.05).Besides,incidence of hypoglycemia in the Novolin 30R group was significantly reduced,length of hospitalization was shorter,and the insulin consume volume was smaller,all showing significant differences(P<0.05).Conclusions: Novolin 30 could improve treatment efficiency and patients' compliance.It's economic and is suitable for widely clinical application.